PlainRecalls
CriticalClass ITerminated

FDA Drug recall · Reported October 8, 2014

Black Ant, 2800 mg, four capsules per box, Manufacturer Qinghai Baojiantang Pharmaceutical Co., Ltd.

Marketed Without an Approved NDA/ANDA: Eugene FDA laboratory analyses determined they contain undeclared sildenafil.

Recall #
D-1613-2014
Affected scope
136 boxes
Initiated
May 5, 2014
Verify with FDA Drug →
View my saved recalls

Eugene Oregon, Inc. recalled Black Ant, 2800 mg, four capsules per box, Manufacturer Qinghai Baojiantang Pharmaceutica… - a critical-severity action.

Black Ant, 2800 mg, four capsules per box, Manufacturer Qinghai Baojiantang Pharmaceutica… was recalled by Eugene Oregon, Inc. in October 8, 2014. Reason: Marketed Without an Approved NDA/ANDA: Eugene FDA laboratory analyses determined they contain undeclared sild…. Check the official notice for the remedy. Verify recall #D-1613-2014 with the FDA Drug before acting.

The recall

Eugene Oregon, Inc. issued this critical-severity FDA Drug recall-Marketed Without an Approved NDA/ANDA: Eugene FDA laboratory analyses determined they contain undeclared sild….

Critical
severity level
Class I
classification
October 8, 2014
reported

Sourced from official FDA Drug enforcement records. Verify recall #D-1613-2014 with the agency before acting. Full product description, hazard, remedy, and related recalls are below.

Recall Insight

This FDA Drug action (record #D-1613-2014) was formally reported on October 8, 2014, with the manufacturer initiating the action on May 5, 2014. It is classified under Critical severity (Class I), with a current status of Terminated. Eugene Oregon, Inc. is listed as the recalling firm, operating out of Levittown, PA. Federal records list the affected scope as 136 boxes.

The documented reason for this recall is: Marketed Without an Approved NDA/ANDA: Eugene FDA laboratory analyses determined they contain undeclared sildenafil. Distribution data in the federal record shows the product reached: To retailers in MD, TX, FL, PA, IL, NJ, IN, LA, WA, ME, SC. Distribution scope directly affects the consumer exposure window and determines whether a recall remains regional or escalates into a nationwide advisory.

Within the same product category the archive holds 6 closely related recalls, 5 from FDA Drug - clustering in a narrow category often points to a systemic quality-control or supplier issue rather than a one-off defect. Always verify the recall number against the official agency record before acting.

Drugs & Medications recalls over time

Where this recall sits in its category - 14,287 drugs & medications recalls on record

-50005001,0001,5002,000 2006201220152018202120242026 263
Severity2487872426High severity (most serious)Moderate severityLow severity
Where this recall sits in the database

Of 101,704 recalls in the database, 24,878 are high severity, 72,426 moderate, and 4,400 low. This recall is classified high severity.

Counts reflect market size and reporting activity, not inherent danger, we do not rank products by risk from raw recall volume.

Severity

Critical

Affected scope

136 boxes

Related Recalls

6

5 from same agency

Product description

Black Ant, 2800 mg, four capsules per box, Manufacturer Qinghai Baojiantang Pharmaceutical Co., Ltd.

Reason for recall

Marketed Without an Approved NDA/ANDA: Eugene FDA laboratory analyses determined they contain undeclared sildenafil.

Recall Profile

Structured summary of the FDA Drug recall record
Attribute Value
Agency U.S. Food and Drug Administration
Severity class Critical (Class I)
Status Terminated
Recall number D-1613-2014
Date reported October 8, 2014
Date initiated May 5, 2014
Recalling firm Eugene Oregon, Inc.
Firm location Levittown, PA
Affected scope 136 boxes
Distribution To retailers in MD, TX, FL, PA, IL, NJ, IN, LA, WA, ME, SC

Profile values are sourced directly from the official FDA Drug enforcement record. Source: U.S. Food and Drug Administration.

What to do with this recall

Match your product against the recall record, then act on the agency remedy.

  • Check the recall number (D-1613-2014) and product description against the item you own. Search the archive
  • Confirm the current status with FDA Drug before acting, recall details can be updated.
  • This is a Class I (high-risk) recall, stop using the product immediately and follow the disposal or return instructions. What to do next

This page summarizes the official FDA Drug record for research and awareness; it is not legal, medical, or safety advice. Verify with the issuing agency before acting.

Frequently Asked Questions

What product was recalled?
Black Ant, 2800 mg, four capsules per box, Manufacturer Qinghai Baojiantang Pharmaceutical Co., Ltd.. Recalled by Eugene Oregon, Inc.. Units affected: 136 boxes.
Why was this product recalled?
Marketed Without an Approved NDA/ANDA: Eugene FDA laboratory analyses determined they contain undeclared sildenafil.
Which agency issued this recall?
This recall was issued by the FDA Drug on October 8, 2014. Severity: Critical. Recall number: D-1613-2014.
Where was the recalled product distributed?
Distribution: To retailers in MD, TX, FL, PA, IL, NJ, IN, LA, WA, ME, SC.
How do I check if my product is affected by a recall?
Check the product description and recall number (D-1613-2014) against your product. Visit the official FDA Drug website for the most current information. You can also use our Recall Checker tool to search by product name or brand.
Should I stop using a recalled medication or medical device?
Do not stop using a recalled medication or device without consulting your healthcare provider first, as abruptly discontinuing treatment could pose its own health risks. Your doctor can advise on alternatives or whether the recall applies to your specific product lot. Check the recall number and lot information against your product packaging.

Nearby Recalls in This Category

Other recalls in the same product category, useful for spotting patterns across the same defect class or manufacturer.

Compare this recall with PRED MILD, prednisolone acetate ophthalmic suspension, USP,… →

Browse all Drugs & Medications recalls →

Every figure on PlainRecalls is rendered directly from official FDA, CPSC and NHTSA recall records, no number is typed in by an editor. This recall: FDA Drug, reported October 8, 2014. Severity classes follow each agency's own taxonomy (FDA Class I/II/III; CPSC and NHTSA by hazard type), and related-recall context is computed across the full archive. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of July 2026.